-
Phase 2
-
-
18+Age Range
-
Active, Not Recruiting
Active, Not Recruiting
An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine whether Nivolumab, in combination with other therapies, is effective in patients with advanced Non-Small Cell lung cancer
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Advanced Non Small Cell Lung Cancer (NSCLC) - Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 1 - Life expectancy of at least 3 months from most recent chemotherapy or immunotherapy treatment - Must have at least 1 lesion with measurable disease Exclusion Criteria: - Subjects with certain mutations that have not been treated with a targeted therapy prior to enrollment - Subjects who need daily oxygen therapy - People with autoimmune disease Other protocol defined inclusion/exclusion criteria could apply
Active Comparator: Nivolumab
Experimental: Nivolumab & BMS-986205
Experimental: Nivolumab & Dasatinib
Experimental: Nivolumab & Ipilimumab
Experimental: Nivolumab & Relatlimab